Physician profile
Aaron Thomas Groth
NPI 1508809021
$4,575.71
in general payments reported to CMS, 2019-2025
42 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $168 · 2021: $169 · 2022: $484 · 2023: $778 · 2024: $962 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875 · Entertainment: $13.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.58 |
| Entertainment | $13.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,042.10 | 2020-2025 | |
| Novo Nordisk INC | $754.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $430.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $299.38 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $267.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $150.15 | 2019-2025 | Farxiga |
| Astellas Pharma US INC | $133.37 | 2019-2025 | Veozah |
| Genzyme Corporation | $131.56 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $106.54 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $103.17 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $99.03 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.45 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.73 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $76.52 | 2019-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $71.65 | 2019-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Groth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.